Skip to main content
Article thumbnail
Location of Repository

Elevated Levels of Methylmalonate and Homocysteine in Parkinson's Disease, Progressive Supranuclear Palsy and Amyotrophic Lateral Sclerosis

By Johannes Levin, Kai Bötzel, Armin Giese, Michael Vogeser and Stefan Lorenzl

Abstract

Background/Aims: Increasing evidence suggests that elevated levels of homocysteine (Hcy) and methylmalonate (MMA) may be involved in the pathogenesis of neurodegenerative diseases. Methods: The urine levels of MMA and serum levels of Hcy as well as folic acid and vitamin B 12 were measured in patients suffering from the distinct neurodegenerative diseases progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), and compared to age-and gender-matched control subjects. Results: We found significantly elevated concentrations of Hcy (PD 15.1, PSP 15.8, ALS 13.9, control 11.2 mu mol/l) and MMA (PD 3.7, PSP 3.1, ALS 3.7, control 1.8 mg/g) in all patient groups in comparison with controls. Levels of Hcy and MMA did not differ significantly between the neurodegenerative diseases. Conclusion: Our findings might imply that Hcy and MMA are released as a consequence of neurodegeneration regardless of the underlying cause and serve as surrogate markers of neurodegeneration. Alternatively they might be directly implicated in the pathogenesis of these diseases. Since elevated levels of both Hcy and MMA are neurotoxic, further studies might investigate the effect of vitamin therapy on disease progression. Copyright (C) 2010 S. Karger AG, Basel

Topics: Medizin, ddc:610
Publisher: Ludwig-Maximilians-Universität München
Year: 2010
DOI identifier: 10.1159/000314841
OAI identifier: oai:epub.ub.uni-muenchen.de:16914
Provided by: Open Access LMU

Suggested articles

Citations

  1. A: Incidence and prevalence of amyotrophic lateral sclerosis in Canada: a systematic review of the literature.
  2. (2004). Diaz-Arrastia R: Levodopa elevates homocysteine: is this a problem? Arch Neurol
  3. (2003). Homocysteine and Alzheimer’s disease.
  4. (2003). Levodopa-induced hyperhomocysteinaemia in Parkinson’s disease.
  5. Litvan I: Unraveling progress i v e s u p r a n u c l e a r p al s y : f r o m t h e b e d s i d e back to the bench. Parkinsonism Relat Disord 2007; 13(suppl 3):S341–S346.
  6. (1995). Montastruc JL: Sulfate and cysteine levels in the plasma of patients with Parkinson’ s disease. Neurotoxicology
  7. Poewe W: The diagnosis of Parkinson’s disease.
  8. Ueland PM: Folate, vitamin B 12 , and serum total homocysteine levels in confirmed Alzheimer disease.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.